Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balances at May. 31, 2024	$ 168,000	$ 54,720,000	$ (102,000)	$ (48,195,000)	$ 6,591,000
Balances, shares at May. 31, 2024	2,103,154
Foreign currency translation			(6,000)		(6,000)
Share-based compensation		77,000			77,000
Share-based compensation, shares
Net income (loss)				(1,316,000)	(1,316,000)
Balances at Aug. 31, 2024	$ 168,000	54,797,000	(108,000)	(49,511,000)	5,346,000
Balances, shares at Aug. 31, 2024	2,103,154
Balances at May. 31, 2024	$ 168,000	54,720,000	(102,000)	(48,195,000)	6,591,000
Balances, shares at May. 31, 2024	2,103,154
Net income (loss)					(3,429,000)
Balances at Feb. 28, 2025	$ 203,000	57,068,000	(113,000)	(51,624,000)	5,534,000
Balances, shares at Feb. 28, 2025	2,546,215
Balances at Aug. 31, 2024	$ 168,000	54,797,000	(108,000)	(49,511,000)	5,346,000
Balances, shares at Aug. 31, 2024	2,103,154
Foreign currency translation			(4,000)		(4,000)
Net proceeds from sales of common stock	$ 15,000	552,000			567,000
Net proceeds from sales of common stock, shares	189,423
Share-based compensation		155,000			155,000
Net income (loss)				(950,000)	(950,000)
Balances at Nov. 30, 2024	$ 183,000	55,504,000	(112,000)	(50,461,000)	5,114,000
Balances, shares at Nov. 30, 2024	2,292,576
Foreign currency translation			(1,000)		(1,000)
Net proceeds from sales of common stock	$ 20,000	1,428,000			1,448,000
Net proceeds from sales of common stock, shares	251,264
Share-based compensation		120,000			120,000
Net income (loss)				(1,163,000)	(1,163,000)
Exercise of stock options		16,000			16,000
Exercise of stock options, shares	2,375
Balances at Feb. 28, 2025	$ 203,000	57,068,000	(113,000)	(51,624,000)	5,534,000
Balances, shares at Feb. 28, 2025	2,546,215
Balances at May. 31, 2025	$ 203,000	57,175,000	(105,000)	(53,168,000)	4,105,000
Balances, shares at May. 31, 2025	2,546,216
Foreign currency translation			3,000		3,000
Net proceeds from sales of common stock	$ 21,000	891,000			912,000
Net proceeds from sales of common stock, shares	258,569
Share-based compensation	$ 1,000	132,000			133,000
Share-based compensation, shares	10,625
Net income (loss)				2,000	2,000
Balances at Aug. 31, 2025	$ 225,000	58,198,000	(102,000)	(53,166,000)	5,155,000
Balances, shares at Aug. 31, 2025	2,815,410
Balances at May. 31, 2025	$ 203,000	57,175,000	(105,000)	(53,168,000)	4,105,000
Balances, shares at May. 31, 2025	2,546,216
Net income (loss)					(2,630,000)
Balances at Feb. 28, 2026	$ 242,000	58,976,000	(103,000)	(55,798,000)	3,317,000
Balances, shares at Feb. 28, 2026	3,029,444
Balances at Aug. 31, 2025	$ 225,000	58,198,000	(102,000)	(53,166,000)	5,155,000
Balances, shares at Aug. 31, 2025	2,815,410
Foreign currency translation			(1,000)		(1,000)
Net proceeds from sales of common stock	$ 11,000	472,000			483,000
Net proceeds from sales of common stock, shares	132,556
Net income (loss)				(1,320,000)	(1,320,000)
Share-based compensation		118,000			118,000
Balances at Nov. 30, 2025	$ 236,000	58,788,000	(103,000)	(54,486,000)	4,435,000
Balances, shares at Nov. 30, 2025	2,947,966
Net proceeds from sales of common stock	$ 1,000	59,000			60,000
Net proceeds from sales of common stock, shares	23,508
Share-based compensation, shares	57,970
Net income (loss)				(1,312,000)	(1,312,000)
Share-based compensation	5,000	129,000			134,000
Balances at Feb. 28, 2026	$ 242,000	$ 58,976,000	$ (103,000)	$ (55,798,000)	$ 3,317,000
Balances, shares at Feb. 28, 2026	3,029,444

BIOMERICA INC 10-Q